NVUS

3 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

SC 13D/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)

SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody IRVINE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond. 2020 a

SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

EFFECT - Novus Therapeutics, Inc. (0001404281) (Filer)

424B2 - Novus Therapeutics, Inc. (0001404281) (Filer)

8-K - Novus Therapeutics, Inc. (0001404281) (Filer)

IRVINE, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced results from a special meeting of stockholders that was held on Friday, December 19, 2020. During the meeting, Novus’ stockholders approved a proposal for the issuance of common shares upon conversion of Series X¹ non-voting convertible preferred stock issued at the time of the company’s acquisition of Anelixis Therapeutics, Inc., and concurrent private placement (PI

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced the appointment of June Lee, M.D., to the company’s Board of Directors. “We are delighted to welcome June to our board of directors as Novus continues on this next phase of its evolution,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Novus Therapeutics, Inc. “Over a twenty plus year career as a clinician, academic, executive, and respected leader in the biote

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today reported its financial results for the quarter ended September 30, 2020, and operational highlights. Recent Business Highlights Completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody Completed a private placement financing expected to result in gross proceeds to

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day. Conference Call Details Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time Toll Fre

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune and neurodegenerative diseases, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a corporate overview to virtual audiences this week at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference and at the Cantor Virtual Global Healthcare Conference. Conferences Details Event:   H.C. Wainwright 22nd Annual Global Investment Conference (virtual) Date:   Wednesday, September 16th

IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. Concurrent with the acquisition of Anelixis, Novus entered into a definitive agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement to a group of institutional accredited investors led by BVF Partners L.P., with p